Hematology and Immunology Strategic Portfolio Supports Sobi's Narrow Moat
Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...